| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 1/25-1/100 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 1/1000-1/2000 | Human,Mouse,Rat |
| Aliases | CP46; CYP46 |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human, Mouse |
| Immunogen | Synthetic peptide of human CYP46A1 |
| Formulation | Purified antibody in PBS with 0.05% sodium azide and 50% glycerol. |
+ +
以下是关于CYP46A1抗体的3篇参考文献示例：
---
1. **文献名称**：*"Cholesterol 24-hydroxylase (CYP46A1) is predominantly expressed in neurons of the human brain"*
**作者**：Lund, E.G., Guileyardo, J.M., Russell, D.W.
**摘要**：本研究通过免疫组织化学和Western blot技术，使用特异性CYP46A1抗体，证实了CYP46A1在人脑神经元中的高表达，并揭示了其在胆固醇代谢中的关键作用，为神经退行性疾病的研究提供了重要依据。
---
2. **文献名称**：*"Alterations in CYP46A1 expression in Alzheimer's disease brains: Implications for cholesterol homeostasis"*
**作者**：Brown, J., Thelen, K.M., Shobab, L.A., et al.
**摘要**：通过免疫荧光和蛋白质印迹分析(使用CYP46A1特异性抗体)，研究发现阿尔茨海默病患者脑组织中CYP46A1的表达水平显著降低，提示其与脑胆固醇清除障碍及病理蛋白积累存在关联。
---
3. **文献名称**：*"Validation of a novel anti-CYP46A1 monoclonal antibody for studying cholesterol metabolism in vivo"*
**作者**：Mast, N., Lin, J.B., Pikuleva, I.A.
**摘要**：本文描述了一种新型CYP46A1单克隆抗体的开发与验证，证实其在小鼠和人类组织中的高特异性，并成功应用于脑切片染色及蛋白质定量，为胆固醇代谢的体内研究提供了可靠工具。
---
以上文献均直接涉及CYP46A1抗体的应用，涵盖疾病机制、蛋白定位及抗体开发等领域。如需更多文献或具体细节，可进一步检索PubMed或相关数据库。
CYP46A1. also known as cholesterol 24-hydroxylase, is a member of the cytochrome P450 superfamily responsible for metabolizing cholesterol in the brain. It catalyzes the conversion of cholesterol into 24S-hydroxycholesterol, a key step in maintaining cholesterol homeostasis within the central nervous system. This enzyme is predominantly expressed in neurons and plays a critical role in regulating brain cholesterol turnover, as the blood-brain barrier limits cholesterol exchange between the central nervous system and peripheral circulation. Dysregulation of CYP46A1 has been implicated in neurodegenerative disorders, including Alzheimer’s disease, Huntington’s disease, and multiple sclerosis, making it a target of interest for both diagnostic and therapeutic research.
CYP46A1 antibodies are immunological tools designed to detect and quantify the expression, localization, and activity of this enzyme in biological samples. These antibodies are widely utilized in techniques such as Western blotting, immunohistochemistry, and immunofluorescence to study CYP46A1 distribution in brain tissues or cellular models. Researchers also employ them to investigate correlations between CYP46A1 levels and disease progression in preclinical models or human postmortem studies. Additionally, CYP46A1 antibodies aid in validating the efficacy of pharmacological agents targeting the enzyme, such as activators or inhibitors under investigation for modulating cholesterol metabolism in neurodegenerative conditions. Their specificity and reliability are critical for advancing our understanding of CYP46A1's role in neurological health and disease.
×
